Trial Profile
Phase I/II study of biweekly nab-paclitaxel in patients with platinum-pretreated non-small cell lung cancer (NJLCG1402)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Oct 2019
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer
- 05 Aug 2019 Status changed from recruiting to completed.
- 09 Oct 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan